Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2012

HIV Drug Consortium Wins Over $5M in EU Funding

  • Mutabilis won €4 million (about $5.3 million) in EU Framework 7 funding to support a collaborative project focused on developing new antiretroviral drugs against HIV. The project, known as HIVINNOV, is being coordinated by Mutabilis and aims to develop a class of antiretrovirals that don’t target HIV directly, but rather impact on the interactions between virus and host. The European consortium could receive up to a total of €6 million (roughly $7.9 million) in funding over the three year term.

    Participants in the project include University College London and the Cancer Research Institute in the U.K., the Academic Medical Center of the University of Amsterdam (the Netherlands), the AIDS Units Clinical Institute of the University of Barcelona (Spain), and researchers at the Institute Cochin (France), and the University Hematology Institute of the Saint Louis Hospital, in Paris (France).

    Now a subsidiary of Pharma Omnium International, Mutabilis was established as an INSERM spin-out in 2001 to discover and develop new therapeutic approaches against bacterial and viral infections.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »